Eli Lilly's stock looked to be slightly reversing its losses in trading ... in our opinion," BofA Securities analyst Tim Anderson wrote in a note to clients Thursday. The overarching concern with the ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY -3.19%). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Leerink Partners handhaafde vrijdag een positieve kijk op het aandeel Eli Lilly (NYSE:LLY) met een Outperform-rating en een koersdoel van $ 944,00. Het standpunt van de firma kwam nadat de aandelen ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

UBS-analisten hebben vrijdag hun vooruitzichten voor aandelen van Eli Lilly (NYSE:LLY) bijgesteld door het koersdoel te verlagen van $ 1.100,00 naar $ 1.050,00. Ondanks de verlaging handhaafden zij ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Bernstein Senior Analyst, US Biopharmaceuticals Courtney ... Despite these headline-grabbing results, Eli Lilly's stock movement remained flat over the last month, aligning with broader market ...

On Tuesday, Eli Lilly and Company (NYSE:LLY) saw its stock price target increased by Cantor Fitzgerald from the previous $815.00 ...